European Researchers Invited to Submit Study Proposals for Bristol-Myers Squibb's Partnering for Cure™ Virology Research

   European Researchers Invited to Submit Study Proposals for Bristol-Myers
          Squibb's Partnering for Cure™ Virology Research Programme

  PR Newswire

  PARIS, April 8, 2014

PARIS, April 8, 2014 /PRNewswire/ --

     Partnering for Cure is Bristol-Myers Squibb's flagship, Pan-European
   scientific initiative supporting breakthrough research and facilitating
  greater collaboration and knowledge-sharing with the virology community 

In advance of this year's International Liver Congress ^TM ^ 2014 in London,
England, Bristol-Myers Squibb invites European researchers to submit
innovative research ideas that aim to cure chronic virological diseases. As
part of Bristol-Myers Squibb's ongoing commitment in virology, these projects
provide an opportunity for researchers, particularly junior faculty and young
investigators, to accelerate novel solutions that could lead to cures in HIV,
hepatitis B (HBV) and hepatitis C (HCV).

This latest round of research applications will be accepted from 1 May to 15
July 2014 and aspiring scientists are encouraged to submit their ideas at . Priority will be given to research
proposals in the area of translational science with a clear relevance for the
clinical development of a cure in viral hepatitis or HIV infection.

Partnering for Cure is led by the Partnering for Cure Faculty, an expert panel
of clinical and research experts from across Europe and focuses on three
pillars - education, scientific exchange and scientific research. The Faculty
will award up to four recipients in a blinded evaluation after applications
close. The four research applicants will share between them just over €300,000
in support from Bristol-Myers Squibb.

"This year, we were proud to announce our first class of Partnering for Cure
research programme recipients in January," said Professor Jürgen Rockstroh,
Partnering for Cure Faculty Chair. "Now we're looking for even more proposals
to expand our clinical network and continuing the fight against chronic viral
diseases through the 2014 Partnering for Cure research programme." 

Matthieu Perreau, Centre Hospitalier Universitaire Vaudois (CHUV) Service
Immunologie et Allergie, Switzerland, was one of the four Partnering for Cure
research programme recipients last year, awarded for his research,
Identification of the memory CD4 T-cell population(s) harbouring replication
competent HIV-1 within lymphoid tissues.

"This grant has provided me with the opportunity to pursue my passion and make
an impact in the virology community," remarks Perreau. "It is an honour to be
part of this exciting initiative, and I look forward to working with my
research colleagues to find a cure."

"Bristol-Myers Squibb has a longstanding vision of continuing to transform the
treatment of viral diseases and fulfilling serious unmet medical needs of
patients," said George Hanna, MD, vice president, HIV Development,
Bristol-Myers Squibb. "We look forward to this year's applications and
supporting the upcoming generation of researchers and scientists who are
dedicated to improving treatments and delivering true advances in patient

The projects that will receive support from Bristol-Myers Squibb will be
announced on World AIDS Day - 1 December 2014.

About Partnering for Cure 

Partnering for Cure is a European medical education programme developed as
part of Bristol-Myers Squibb's ongoing commitment to virology research,
education and transforming clinical outcomes for patients with chronic viral
diseases. The programme focuses on recent and ongoing cure research in HIV,
HBV and HCV.

The objectives of the programme are to:

  *Provide medical education to physicians interested in virology cure
  *Provide support to researchers active in virology cure research
  *Provide a forum for physicians and researchers to discuss advances in
    virology cure

The Partnering for Cure initiative reinforces Bristol-Myers Squibb's
commitment in virology, which is rooted in the company's legacy in virology
and ongoing research in HIV and viral hepatitis. Chronic viral infections make
a substantial contribution to the burden of chronic diseases and premature
mortality worldwide. In December 2012, the Global Burden of Disease Study
reported 1,465,000 deaths caused by HIV/AIDS and 1,445,000 deaths caused by
viral hepatitis in 2010. ^[i] Infections with hepatitis B and C viruses also
cause an estimated 57 percent of cases of liver cirrhosis and 78 percent of
cases of primary liver cancer annually. ^[ii] Whilst important advances have
been made over the last decade significant unmet needs and the opportunity for
cure remains , particularly in HIV.

Bristol-Myers Squibb's Commitment to Virology 

For over 20 years, Bristol-Myers Squibb has worked collaboratively with the
virology community to help meet the needs of patients living with HIV, HBV and
HCV - by providing and developing medicines such as Zerit ^® , Videx ^® ,
Sustiva ^® , Atripla ^[ ^®* ^] , Reyataz ^® , Baraclude ^® , supporting
clinical research on new innovative compounds, supporting disease education
efforts, and improving access to medicines in the developing world.

Bristol-Myers Squibb supports a number of scientific and educational programs
within the virology community around the world that encompass disease
education, disease awareness and sharing of best practices. In addition to
Partnering for Cure these include SHE ^® ( S trong,  H IV positive,  E
mpowered Women/ S trong,  H IV positive Women  E ducational Programme) , a
comprehensive and innovative programme for women living with HIV and their
healthcare providers, PATH B ^® ( P atients and professionals  a cting  t
ogether for  h epatitis  B ), a joint initiative between hepatitis patient
groups and hepatologists to provide comprehensive information and support for
patients with chronic hepatitis B.

Additionally, Bristol-Myers Squibb Foundation's philanthropic and educational
programmes, such as Secure the Future ^® and Delivering Hope ^® aim to support
people living with HIV in Africa and with viral hepatitis in Asia, through
numerous private-public partnerships and community based projects.


Prepared April 2014

*Atripla® is a trademark of Bristol-Myers Squibb Co. and Gilead Sciences,

i. Global and regional mortality from 235 causes of death for 20 age groups in
1990 and 2010: a systematic analysis for the Global Burden of Disease Study
2010, The Lancet, Volume 380, No9859, Dec 15, 2012 pp2095-2128

ii. WHO and WHA, Global Policy Report on the Prevention and Control of Viral
Hepatitis, 2013,

Contact: Media: Jeff Smith +33(0)6-03-99-40-18
Press spacebar to pause and continue. Press esc to stop.